Nov 26

FDA rejects Avanir’s migraine drug-device – Reuters


FDA rejects Avanir's migraine drug-device
Reuters
(Reuters) - The U.S. Food and Drug Administration rejected Avanir Pharmaceuticals Inc's migraine drug device, a few weeks after the regulator had raised questions regarding some data submitted as part of the marketing application. Earlier this month ...
Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA ...MarketWatch

all 1 news articles »

Nov 26

FDA rejects Avanir’s migraine drug-device – Reuters


FDA rejects Avanir's migraine drug-device
Reuters
Nov 26 (Reuters) - The U.S. Food and Drug Administration rejected Avanir Pharmaceuticals Inc's migraine drug device, a few weeks after the regulator had raised questions regarding some data submitted as part of the marketing application. Earlier this ...
Avanir to Provide More Human-Factor Data for Migraine TreatmentWall Street Journal
Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA ...MarketWatch

all 4 news articles »

Nov 26

A New Mechanism for Migraine Prevention – Medscape

Nov 26

A New Mechanism for Migraine Prevention – Medscape


A New Mechanism for Migraine Prevention
Medscape
This is the Medscape Neurology Minute. I am Dr Alan Jacobs. Two phase 2 studies presented at the 66th annual meeting of the American Academy of Neurology have tested the ability of monoclonal antibodies to prevent migraine headaches. In both studies ...

Nov 26

Local researchers develop nasal spray for quick relief of migraines – KSL.com


Local researchers develop nasal spray for quick relief of migraines
KSL.com
A new nasal spray intended to relieve migraines is being developed by Venkata Yellepeddi and his team at the Roseman University of Health Sciences, which is located in South Jordan. Yellepeddi said the spray, a new formulation of prochlorperazine, ...

and more »

Nov 26

Another Step Forward for Migraine Biomarker – Medscape

Nov 25

Migraine market set for fast growth, driven by two novel therapies – PharmaTimes


Migraine market set for fast growth, driven by two novel therapies
PharmaTimes
Allergan's Botox (onabotulinumtoxinA) continues to drive growth in the prophylactic market. Physicians are becoming increasingly comfortable with prescribing it for chronic migraine, especially given its very favourable tolerability profile and few ...

Nov 25

Migraine market set for fast growth, driven by two novel therapies – PharmaTimes

Nov 25

Scientists discover ‘stroke protection gene’ – that also guards against heart … – The Independent

Nov 25

Scientists discover ‘stroke protection gene’ – that also guards against heart … – The Independent

Older posts «